

Agents of exposure in transgender patient cases managed by a toxicologist: An analysis of the toxicology investigators consortium (ToxIC) registry

Olivia A. Hardy

Lehigh Valley Health Network, olivia.hardy@lvhn.org

Alexandra Amaducci

Lehigh Valley Health Network, Alexandra.Amaducci@lvhn.org

Judith Sabino

Lehigh Valley Health Network, judith.sabino@lvhn.org

Beth Careyva

Lehigh Valley Health Network, beth_a.careyva@lvhn.org

Matthew D. Cook DO

Lehigh Valley Health Network, Matthew_D.Cook@lvhn.org

See next page for additional authors

Follow this and additional works at: <https://scholarlyworks.lvhn.org/family-medicine>



Part of the [Public Health Education and Promotion Commons](#)

Let us know how access to this document benefits you

Published In/Presented At

Beauchamp G, Hardy O, Amaducci A, Sabino J, Careyva B, Cook M, Katz K, Rayl-Greenberg M, Sumaitis R, Koons A, Zackary J. (October 25, 2021). *Agents of exposure in transgender patient cases managed by a toxicologist: An analysis of the toxicology investigators consortium (ToxIC) registry* [Poster]. Poster presented at American College of Emergency Physicians, ACEP, Boston, MA

This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an authorized administrator. For more information, please contact LibraryServices@lvhn.org.

Authors

Olivia A. Hardy, Alexandra Amaducci, Judith Sabino, Beth Careyva, Matthew D. Cook DO, Kenneth Katz, Marna Greenberg, Ryan Surmaitis DO, Andrew Koons, Joseph B. Zackary MD, and Gillian A. Beauchamp MD

Agents of Exposure in Transgender Patient Cases Managed by a Toxicologist: An Analysis of the Toxicology Investigator's Consortium (ToxIC) Registry

Olivia A. Hardy, BS, Alexandra M. Amaducci, DO, Judith N. Sabino, MPH, Beth A. Careyva, MD, Matthew D. Cook, DO, Kenneth D. Katz, MD, Marna Rayl-Greenberg, DO, MPH
Ryan M. Surmaitis, DO, Andrew L. Koons, DO, Joseph B. Zachary, MD, Gillian A. Beauchamp, MD

On behalf of the Toxicology Investigators Consortium (ToxIC) Study Group

Lehigh Valley Health Network/University of South Florida Morsani College of Medicine, Lehigh Valley Campus, Allentown, PA

Study Objective

Little is known regarding trends in poisonings within the transgender community. We set out to review medical encounters managed by a medical toxicologist and provide descriptive data in trends among types of exposures within the transgender demographic.

Methods

The Toxicology Investigators Consortium (ToxIC) database was created in 2010 by the American College of Medical Toxicology (ACMT) to compile data recorded by medical toxicologists. In January 2017 the data field for transgender (and, if transgender, male to female or female to male) was added to the ToxIC form. Between January, 2017–December, 2020 a retrospective ToxIC database review of transgender cases including descriptive demographics was performed.


Results

There were 195 transgender cases. Among these, 61.5% (N=120) were female-to-male, 32.8% (N=64) were male-to-female, and 5.6% (N=11) were gender nonconforming. In regards to race, 63.1% (N=123) were Caucasian, 6.2% (N=12) Black/African American, 3.6% (N=7) Asian, 2% (N=4) mixed race, 1% (N=2) American Indian/Alaskan Native, 0.5% (N=1) Native Hawaiian or Pacific Islander, and 23.6% (N=46) unknown. In regards to ethnicity, 7.2% (N=14) of cases were Latino/Hispanic, 62.6% (N=122) not Latino/Hispanic, and 30.2% (N=59) unknown. Of the 195 transgender cases, 49.7% (N=97) were 13-18 years old, 46.2% (N=90) 19-65 years old, 3.1% (N=6) 7-12 years old, and 1% (N=2) 66-89 years old. In this cohort there were no reported deaths.

Overall, 88.2% (N=172) of the poisonings involved pharmaceutical drugs – 98.3% (N=169) of which were intentional ingestions. Twenty-one percent

(N=41) were analgesics, 20% (N=39) antidepressants, 8.7% (N=17) anti-cholinergic/anti-histamines, 7.2% (N=14) antipsychotics, 7.2% (N=14) anticonvulsants/mood stabilizers, 4.6% (N=9) cardiovascular medications, 4.1% (N=8) opioids, 3.6% (N=7) ethanol; 2.6% (N=5) sympathomimetics, 2.6% (N=5) household substances, 2% (N=4) cough & cold medications, 2% (N=4) sedative/hypnotic/muscle relaxants, 1.5% (N=3) other pharmaceuticals, 1% (N=2) psychoactive substances, 1% (N=2) diabetic medications, 1% (N=2) caustic ingestions, 1% (N=2) toxic alcohols (specifically ethylene glycol and isopropanol); 0.5% (N=1) metals, 0.5% (N=1) herbals/dietary supplements/vitamins, 0.5% (N=1) GI medications, 0.5% (N=1) envenomations; 0.5% (N=1) chemotherapeutic/immune medications, 0.5% (N=1) antimicrobials, 0.5% (N=1) anticoagulants, and 5.1% (N=10) unknown or not reported.

195 TRANSGENDER CASES



Conclusion

Among transgender patients with poisonings reported to the ToxIC registry, the majority were adolescent Caucasians who ingested either analgesic or psychotropic medications. These data may be helpful to develop poisoning prevention practices in this vulnerable population.

This study was funded, in part, by the Dorothy Rider Pool Health Care Trust Research and Development Award for Clinical Excellence.